Life Sciences

Toxicologist and Pace® Regulatory Expert Sherry Sachdeva to discuss industry updates & impacts MINNEAPOLIS, MN – March 10, 2026 The European Union has expanded how endocrine disruptors are care classified, introducing new hazard classes under its Classification, Labeling and Packaging (CLP) Regulation that could impact global manufacturers. Pace® Life Sciences is hosting a free, virtual webinar led by Sherry Sachdeva, […]

Senior Expert, Dr. Julie Barnhill, to share practical strategies for ensuring GxP compliance in virtual and hybrid pharma companies MINNEAPOLIS, MN – February 20, 2026 As pharmaceutical companies increasingly rely on outsourced operations, maintaining GxP compliance has become a critical and challenging element of sponsorship oversight. Pace® Life Sciences, a U.S.-based contract development and manufacturing

Chief Scientific Officer of Pace® Life Sciences Joins Industry Leaders at Advancing Drug Development Forum (ADDF) to Collaborate on Technologies for Non-Traditional Molecules  BOSTON, MA – December 5, 2025 – Pace® Life Sciences, a U.S.-based CRDMO and FDA-registered GMP Analytical Testing lab, announced that Chief Scientific Officer Frank Tagliaferri, Ph.D., will join a round table

Pace® expert to leverage extensive knowledge to provide guidance on risk assessments for pharmaceutical and biopharmaceutical companies MINNEAPOLIS, MN – September 4, 2025 – Pace® Life Sciences, a U.S.-based contract, research, development and manufacturing organization (CRDMO) and a division of Pace®, a Science and Technology Company, is hosting a free virtual webinar providing an overview of

Company commitment to quality excellence confirmed during FDA Inspection MINNEAPOLIS, MN – August 21, 2025– Pace® Life Sciences, a U.S.-based contract, research, development and manufacturing organization (CRDMO) and full-service FDA-registered GMP Analytical Testing laboratory announced today that its San German, Puerto Rico site has received a positive FDA Inspection of its quality systems and client data

The United States is global powerhouse in pharmaceutical contract development and manufacturing, home to some of the world’s most advanced CDMOs. The U.S. combines scale, scientific leadership, and advanced regulatory infrastructure to support drug development from early-stage innovation to commercial manufacturing. The U.S. currently leads biomedical research globally, conducting roughly 46% of all life‑sciences R&D. The contract manufacturing

Company reopens state-of-the-art isolated vial filling line at Aseptic Fill-Finish Center of Excellence MINNEAPOLIS, MN – August 12, 2025 – Pace® Life Sciences, a U.S.-based contract, research, development and manufacturing organization (CRDMO) and full-service FDA-registered GMP Analytical Testing laboratory re-opened its 33,000 square foot facility in Salem, NH with advanced technologies to support small batch manufacturing.

July 16 open house highlights expanded sterile filling contract manufacturing capabilities for small and large molecules Minneapolis, MN – July 2, 2025 – Pace® Life Sciences, LLC, a U.S.-based contract research, development, and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, builds upon its growth in the pharma and biotech

Company confirms high standards for data integrity and quality systems  MINNEAPOLIS, MN, May 20, 2025 Pace® Life Sciences, a U.S.-based full-service FDA-registered GMP Analytical Testing laboratory and contract, research, development and manufacturing organization (CRDMO) and a Division of Pace®, a Science and Technology Company, announced today a successful Pre-Approval Inspection (PAI) from The Food & Drug